论文部分内容阅读
在流行性出血热发热期应用重组人干扰素α-2b治疗16名患者，使患者发热期、少尿期、多尿期的持续时间较对照组均明显缩短，与对照组1：1配比进行t检验，两级各期的持续时间呈显著性差异（P＜0.05），具统计学意义．另外经干扰素治疗组患者越过少尿期直接由发热期进入多尿期的越期率也高于对照组。由此证实，对流行性出血热早期应用干扰素治疗，可以减轻患者病型，缩短病程，值得在临床中推广。
In the fever of epidemic hemorrhagic fever using recombinant human interferon α-2b treatment of 16 patients, so that patients with fever, oliguria, polyuria period was significantly shorter than the control group, compared with the control group 1: 1 ratio T test, the two stages of the duration was significantly different (P <0.05), with statistical significance. In addition, patients in the interferon group crossed the oliguria period directly from the fever period into the polyuria overdraft rate is also higher than the control group. This confirmed that early application of interferon treatment of epidemic hemorrhagic fever can reduce the patient’s type, shorten the course of the disease, it is worth in the clinical promotion.